Probiotec Limited (ASX:PBP) insider Jonathan Wenig acquired 47,500 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were bought at an average cost of A$1.90 ($1.35) per share, for a total transaction of A$90,250.00 ($64,007.09).

Shares of PBP traded down A$0.04 ($0.03) during mid-day trading on Wednesday, reaching A$1.88 ($1.33). 26,253 shares of the company’s stock were exchanged. The stock has a market capitalization of $140.58 million and a PE ratio of -134.29. The company has a debt-to-equity ratio of 67.32, a current ratio of 1.76 and a quick ratio of 1.05. Probiotec Limited has a 52-week low of A$1.50 ($1.06) and a 52-week high of A$2.48 ($1.76). The business’s fifty day simple moving average is A$1.92 and its 200-day simple moving average is A$2.00.

About Probiotec

Probiotec Limited develops, manufactures, and sells pharmaceutical, consumer health, and nutraceutical products in Australia and internationally. The company operates in three segments: Branded Pharmaceuticals, Contract Manufacture, and Obesity and Weight Management. It primarily engages in the contract manufacturing of pharmaceutical, food, and animal nutrition products for pharmaceutical and food companies; manufacture and sale of a range of obesity and weight management products in various channels, including FMCG, pharmacy, health food stores, and online; and provision of Celebrity Slim and Impromy weight loss programs.

Recommended Story: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for Probiotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Probiotec and related companies with MarketBeat.com's FREE daily email newsletter.